| Trial ID: | L4279 |
| Source ID: | NCT04729296
|
| Associated Drug: |
Golimumab
|
| Title: |
Anti-TNFα to Delay or Prevent Progression to Stage 3 T1D
|
| Acronym: |
|
| Status: |
WITHDRAWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 1
|
| Interventions: |
DRUG: Golimumab|DRUG: Placebo
|
| Outcome Measures: |
Primary: The primary outcome is the elapsed time from random treatment assignment to the development of diabetes (T1D) or time of last contact among those randomized, The primary outcome is the elapsed time from random treatment assignment to the development of diabetes (T1D) or time of last contact among those randomized, 6 years |
|
| Sponsor/Collaborators: |
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Collaborators: University of South Florida
|
| Gender: |
ALL
|
| Age: |
CHILD, ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
0
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION
|
| Start Date: |
2021-07-01
|
| Completion Date: |
2027-07-01
|
| Results First Posted: |
|
| Last Update Posted: |
2021-12-02
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT04729296
|
